NewLimit improves how precisely its liver medicine targets liver cells 8-fold without losing potency

NewLimit/Hepatocyte epigenetic reprogramming

NewLimit reported a version of its lead liver medicine with 8 times the specificity for liver cells and 1.6 times the potency of the earlier prototype, achieving >100-fold selectivity for liver tissue.

• 8-fold improvement in hepatocyte specificity compared to off-target cells; 1.6-fold potency increase through mRNA optimization.
• Optimized medicine now demonstrates >100-fold selectivity for liver cells, improving therapeutic window.
• Progress finalizes the payload for human clinical trials within several years.